John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Precision medicine in hepatocellular carcinoma Volume 27, supplement 1, Mai 2020

Figures

  • Figure 1
  • Figure 2

Tables

Authors
1 Hôpitaux Universitaires Paris-Seine-Saint-Denis, Hôpital Jean-Verdier, Service d’hépatologie, Avenue du 14 juillet, 93140 Bondy
2 Unité de Formation et de Recherche Santé Médecine et Biologie Humaine, Université Paris 13, Communauté d’Universités et Etablissements Sorbonne Paris Cité, Paris
3 Centre de Recherche des Cordeliers, Sorbonne Universités, Inserm, UMRS-1138, Sorbonne Université, F-75006 Paris
4 Functional Genomics of Solid Tumors, USPC, Université Paris Descartes, Université Paris Diderot, Université Paris 13, F-75006 Paris
* Correspondance

Hepatocellular carcinoma (HCC) is a heterogeneous tumor at the molecular level. Next generation sequencing has allowed to identify the mutations in driver genes of the main signaling pathways involved in liver carcinogenesis: Telomere maintenance, cell cycle gene, Wnt/B-catenin, epigenetic modifier gene, oxidative stress, akt/mtor and ras/raf map kinase pathways. These genetic alterations are associated with transcriptomic subgroup, clinical and histological features and define a genotype/phenotype classification of HCC in different molecular subgroups. The refinement of HCC genomic will be helpful to identify prognostic molecular signatures, biomarkers predictive of response to systemic treatments and new therapeutic targets for advanced HCC.